JP2024507991A - 激越を処置するための方法及び組成物 - Google Patents

激越を処置するための方法及び組成物 Download PDF

Info

Publication number
JP2024507991A
JP2024507991A JP2023552197A JP2023552197A JP2024507991A JP 2024507991 A JP2024507991 A JP 2024507991A JP 2023552197 A JP2023552197 A JP 2023552197A JP 2023552197 A JP2023552197 A JP 2023552197A JP 2024507991 A JP2024507991 A JP 2024507991A
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
latrepirdine
dosage form
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023552197A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024507991A5 (https=
Inventor
ビーボ， マイケル デ
フリソ ポストマ，
デイビッド クリスティアン ハンリー，
ヴァスクマール カクマヌ，
スベンドゥ セト，
ディネシュ クマール ドゥル，
Original Assignee
バイオエクセル セラピューティクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオエクセル セラピューティクス，インコーポレイテッド filed Critical バイオエクセル セラピューティクス，インコーポレイテッド
Publication of JP2024507991A publication Critical patent/JP2024507991A/ja
Publication of JP2024507991A5 publication Critical patent/JP2024507991A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2023552197A 2021-02-26 2022-02-25 激越を処置するための方法及び組成物 Pending JP2024507991A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163154281P 2021-02-26 2021-02-26
US63/154,281 2021-02-26
PCT/US2022/017963 WO2022183029A1 (en) 2021-02-26 2022-02-25 Methods and compositions for treating agitation

Publications (2)

Publication Number Publication Date
JP2024507991A true JP2024507991A (ja) 2024-02-21
JP2024507991A5 JP2024507991A5 (https=) 2025-03-03

Family

ID=83048476

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023552197A Pending JP2024507991A (ja) 2021-02-26 2022-02-25 激越を処置するための方法及び組成物

Country Status (7)

Country Link
US (2) US20240139169A1 (https=)
EP (1) EP4297871A4 (https=)
JP (1) JP2024507991A (https=)
CN (1) CN117412747A (https=)
CA (1) CA3208828A1 (https=)
TW (1) TW202302094A (https=)
WO (1) WO2022183029A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL267689B2 (en) 2016-12-31 2025-05-01 Bioxcel Therapeutics Inc Use of sublingual dexmedetomidine for the treatment of agitation
BR112020026672A2 (pt) 2018-06-27 2021-03-30 Bioxcel Therapeutics, Inc. Formulações de filme contendo dexmedetomidina e métodos para produzi-las
BR112022000992A2 (pt) 2019-07-19 2022-06-14 Arx Llc Regimes de tratamento de dexmedetomidina não sedantes
EP4078055B1 (en) * 2019-12-16 2025-03-12 Northwestern University Method for forming a circular pellet
TW202416979A (zh) * 2022-08-31 2024-05-01 美商百歐克斯賽爾治療公司 用於治療急性壓力症之方法及組合物
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
WO2024211911A1 (en) * 2023-04-07 2024-10-10 Oaktree Fund Administration, Llc Methods for treating depressive states
EP4731214A1 (en) * 2023-06-23 2026-04-29 BioXcel Therapeutics, Inc. Dexmedetomidine treatment regimens

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070117835A1 (en) * 2005-10-04 2007-05-24 David Hung Methods and compositions for treating Huntington's disease
JP2010535220A (ja) * 2007-08-01 2010-11-18 メディベイション ニューロロジー， インコーポレイテッド 抗精神病用の併用療法剤を使用する統合失調症の治療のための方法および組成物
JP2020503323A (ja) * 2016-12-31 2020-01-30 バイオエクセル セラピューティクス，インコーポレイテッド 激越の治療のための舌下デクスメデトミジンの使用
WO2021016112A2 (en) * 2019-07-19 2021-01-28 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1138164A1 (ru) * 1963-04-25 1985-02-07 Shadurskij Konstantin S Антигистаминное средство "димебон
JP2010540454A (ja) * 2007-09-21 2010-12-24 アカディア ファーマシューティカルズ，インコーポレーテッド ピマバンセリンと他の薬剤との併用投与
WO2009039461A2 (en) * 2007-09-21 2009-03-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
EP2340254B8 (en) * 2008-09-15 2014-05-21 Biovista, Inc. Compositions and methods for treating epilepsy
TR200903014A1 (tr) * 2009-04-17 2010-11-22 Sanovel İlaç San. Ve Ti̇c. A.Ş. Oral yolla dağılan dimebolin bileşimleri.
WO2011039686A1 (en) * 2009-09-30 2011-04-07 Pfizer Inc. Latrepirdine oral sustained release dosage forms
US20120202823A1 (en) * 2010-12-23 2012-08-09 Alkermes, Inc. Multi-API Loading Prodrugs

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070117835A1 (en) * 2005-10-04 2007-05-24 David Hung Methods and compositions for treating Huntington's disease
JP2010535220A (ja) * 2007-08-01 2010-11-18 メディベイション ニューロロジー， インコーポレイテッド 抗精神病用の併用療法剤を使用する統合失調症の治療のための方法および組成物
JP2020503323A (ja) * 2016-12-31 2020-01-30 バイオエクセル セラピューティクス，インコーポレイテッド 激越の治療のための舌下デクスメデトミジンの使用
WO2021016112A2 (en) * 2019-07-19 2021-01-28 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Also Published As

Publication number Publication date
EP4297871A4 (en) 2025-01-01
TW202302094A (zh) 2023-01-16
EP4297871A1 (en) 2024-01-03
CA3208828A1 (en) 2022-09-01
CN117412747A (zh) 2024-01-16
US20250228833A1 (en) 2025-07-17
WO2022183029A1 (en) 2022-09-01
US20240139169A1 (en) 2024-05-02

Similar Documents

Publication Publication Date Title
JP2024507991A (ja) 激越を処置するための方法及び組成物
JP6929479B2 (ja) 激越の治療のための舌下デクスメデトミジンの使用
JP4881268B2 (ja) 苦味が抑制された経口製剤
EP2319498A1 (en) Taste-masked multiparticulate pharmaceutical composition comprising a drug-containing core particle and a solvent-coacervated membrane
JP2013539790A (ja) メマンチンを含む鎮咳組成物
JP5259880B2 (ja) 経口剤
JP2009114113A (ja) 口腔内崩壊錠及びその製造方法
JPWO2002096406A1 (ja) 医薬組成物
JP2008531681A (ja) 炭酸マグネシウムヘビーを含む速崩壊型製剤
JP2007510733A (ja) プロトンポンプ阻害剤および睡眠剤の併用
JP2006528181A (ja) 酸分泌を阻害するために有用な薬学的製剤ならびにそれらを作製および使用する方法
EP3216445A1 (en) Oral therapeutic compound delivery system
US20130274342A1 (en) Compositions and methods for treating cough
KR20180097581A (ko) 1-(3-(2-(1-벤조티오펜-5-일)에톡시)프로필)아제티딘-3-올 또는 그 염을 포함하는 정제
JP2023545372A (ja) デクスメデトミジン塩酸塩を用いた双極性障害及び精神病の治療
CN1378452A (zh) 含有米氮平的口内崩解组合物
RS60203B1 (sr) Pedijatrijska formulacija
KR20140076998A (ko) 에스오메프라졸 유리염기 또는 그의 알칼리염을 포함하는 고미가 차폐된 약학 제제 및 이의 제조방법
JP6061924B2 (ja) 口腔内分散性製剤
KR20200131913A (ko) 플루르비프로펜을 포함하는 약학적 조성물
JP2025529123A (ja) 急性ストレス障害を処置するための方法及び組成物
US20080014261A1 (en) Non-narcotic biphasic release compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction
JP2006076956A (ja) 胃炎の治療・予防用配合剤
WO2025128666A1 (en) Combination of latrepirdine and a pharmacokinetic stabilizer
US20080008772A1 (en) Narcotic biphasic release compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250220

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260423